|
業績
|
| |
■主な英文原著
|
| |
2021年
- Morishita S, Ochiai T, Misawa K, Osaga S, Inano T, Fukuda Y, Edahiro Y, Ohsaka A, Araki M, Komatsu N. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. Int J Hematol. 2021.【Epub ahead of print】
2020年
- Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki Y, Ito M, Araki M, Komatsu N. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci. 2020. 【Epub ahead of print】
- Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, Hironaka Y, Mizukami Y, Kihara Y, Takei H, Nudejima M, Koike M, Ohsaka A, Komatsu N. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia. 2020 Feb;34(2):499-509.
2019年
- Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, Komatsu N. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol. 2019 Oct;187(1):e27-e31.
- Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol. 2019 Jun;102(6):516-520.
- Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica. 2019 Nov;104(11):e506-e509.
- Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A, Komatsu N. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia. 2019 Jan;33(1):122-131.
2018年
- Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol. 2018;181(6):791-802.
- Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol. 2018;100(6):544-9.
- Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107(6):673-80.
- Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018. [Epub ahead of print]
2017年
- Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: comparison with the 2008 WHO diagnostic criteria. Am J Hematol. 2017;92(7):E128-E130.
- Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N. Histone Acetyltransferase PCAF is Required for All-trans Retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem. 2017 Feb 17;292(7):2815-2829.
- Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol. 2017;105(3):309-317.
- Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol. 2017;105(3):353-360.
2016年
- Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, and Komatsu N. Activation of the thrombopoietin receptor by mutant carleticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127(10):1307-16.
- Baba T, Tanabe Y, Yoshikawa S, Yamanishi Y, Morishita S, Komatsu N, Karasuma H, Hirao A, and Mukaida N. MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice. Blood 2016;127(21):2607-17.
- Liew EL, Araki M, Hironaka Y, Mori S, Tan TZ, Morishita S, Edahiro Y, Ohsaka A, Komatsu N. Identification of AIM2 as a downstream target of JAK2V617F. Exp Hematol Oncol. 2016;5:2.
- Iizuka K, Yokomizo T, Watanabe N, Tanaka Y, Osato M, Takaku T, Komatsu N. Lack of Phenotypical and Morphological Evidences of Endothelial to Hematopoietic Transition in the Murine Embryonic Head during Hematopoietic Stem Cell Emergence. PLoS One. 2016;11(5):e0156427.
- Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H, Maeda M, Yagita H, Komatsu N, Hino O. Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. PLoS One. 2016;11(3):e0150496.
- Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, Nagao M, Takaku T, Komatsu N, Kaneko K. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016;21(5):683-689.
2015年
- Yasuda H, Tsutsui M, Tanaka M, Araki M, Morishita S, Sasaki M, Ohsaka A, Komatsu N. Accurate flow cytometric gating of the large lymphocyte region is a powerful screening method for detecting hairy cell leukemia presenting with a low tumor burden. Internal Med. 2015;54(10):1287-9.
- Yasuda H, Fujiwara N, Ishizaki Y, Komatsu N. Anemia attributed to vitamin B6 deficiency in post-pancreaticoduodenectomy patients. Pancreatol. 2015;15(1):81-3.
- Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46-8.
- Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, Noguchi M, Koike M, Sato E, Ohsaka A, Komatsu N. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol. 2015;101(2):148-53.
- Ohsaka A, Hirota-Komatsu S, Araki M, Komatsu N. Platelet-derived growth factor receptors form complexes with neuropilin-1 during megakaryocytic differentiation of thrombopoietin-dependent UT-7/TPO cells. Biochem Biophys Res Commun. 2015;459(3):443-9.
- Morishita S, Takahashi K, Araki M, Hironaka Y, Sunami Y, Edahiro Y, Tsutsui M, Ohsaka A, Tsuneda S, Komatsu N. Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation. PLoS One. 2015;10(3):e0122003.
- Harada-Shirado K, Ikeda K, Ogawa K, Ohkawara H, Kimura H, Kai T, Noji H, Morishita S, Komatsu N, Takeishi Y. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br J Haematol. 2015;168(3):338-49.
2014年
- Takei H, Morishita S, Araki M, Edahiro Y, Sunami Y, Hironaka Y, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Komatsu N. Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One. 2014;9(8):e104958.
- Mitsumori T, Nozaki Y, Kawashima I, Yamamoto T, Shobu Y, Nakajima K, Morishita S, Komatsu N, Kirito K. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells. Exp Hematol. 2014;42(9):783-92 e1.
- Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, Tsutsui M, Hosone M, Hirano T, Gotoh A, Komatsu N. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. Int J Hematol. 2014;100(4):370-8.
- Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, Shirane S, Tsutsui M, Noguchi M, Koike M, Imai K, Kirito K, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Araki M, Komatsu N. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99(5):625-34.
|
| |
■英文総説・著書など
|
| |
2019年
- De Marchi F, Araki M, Komatsu N. Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia. Expert Rev Hematol. 2019. [Epub ahead of print]
2018年
- Araki M, Komatsu N. Mutant molecular chaperone activates cytokine receptor as a homomultimer. Oncotarget. 2018 Oct 16;9(81):35201-35202.
2017年
- Araki M, Komatsu N. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci. 2017 Jul 25. doi: 10.1111/cas.13327. [Epub ahead of print]
- Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017 Jun;105(6):743-747.
2014年
- Komatsu N. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia. Int J Hematol. 2014 Jul;100(1):16-7.
|
| |
■和文総説・著書など（抜粋）
|
| |
2018年
- 小松則夫. JAK阻害薬における感染症とその対策. 血液フロンティア. 2018;5:49−58.
- 小松則夫. 本能性血小板血症. WHO血液腫瘍分類 WHO分類2017をうまく活用するために改訂版 2018:53-5.
- 枝廣陽子, 小松則夫. 真性赤血球増加症（真性多血症）. WHO血液腫瘍分類 WHO分類2017をうまく活用するために改訂版 2018:43-6.
- 枝廣陽子, 小松則夫. 骨髄増殖性腫瘍の臨床経過とJAK2変異アリル定量. 血液内科 科学評論社. 2018;76(5):620-5.
- 桐戸敬太, 小池道明 , 野口雅章 , 木崎昌弘, 杉本由香, 片山直之 , 土橋史明, 薄井紀子, 小松則夫. 骨髄増殖性腫瘍症例および健常者を対象にした 新規 JAK2 V617F 変異量測定キットの臨床性能試験. 臨床血液. 2018;59(6):669-74
2017年
- 小松則夫(企画). 骨髄増殖性腫瘍（MPN）の分子病態と診断・治療のup-to-date. 最新医学. 2017.
- 小松則夫. 小特集 骨髄線維症（MF） 〜分子病態の解明から新規治療薬の開発まで〜
序 〜骨髄線維症の現状と展望〜. 血液フロンティア. 2017:99〜103.
2016年
- 小松則夫. 骨髄増殖性腫瘍：診断における遺伝子変異の意義と問題点. 日本検査血液学会雑誌; 17(3), 2016.
- 小松則夫. Ph陰性古典的骨髄増殖性腫瘍の分子病態と分子標的薬の開発. 日本検査血液学会雑誌; 17(2), 2016.
- 今井美沙, 荒木真理人, 森下総司, 小松則夫. 骨髄増殖性腫瘍をひき起こす変異型calreticulinによるTPO受容体の活性化機構. 血液内科; 173(6), 2016.
- 小松則夫. 血液・リンパ系腫瘍再発・難治性造血器腫瘍の治療−新規・追加承認薬とその位置付け− I. 骨髄線維症・真性赤血球増加症に対するルキソリチニブ治療. がんと化学療法; 43(5):530-534, 2016.
- 荒木真理人，森下総司，小松則夫. 骨髄増殖性腫瘍の遺伝子変異 最近の知見. 臨床血液; 57(12):2526-2534, 2016.
2015年
- 小松則夫. 貧血：基礎と最近の話題. 日本内科学会雑誌; 104(7): 1361-1366, 2015.
- 小松則夫. 血液領域の分子標的治療薬 ルキソリチニブ. 最新医学別冊 診断と治療のABC; 102: 48-60, 2015.
- 小松則夫. JAK2変異陰性骨髄増殖性腫瘍におけるcalreticulin変異. 中外医学社 Annual Review血液2015; 2015.
- 小松則夫. JAK2変異を伴う骨髄増殖性腫瘍の臨床病理. 病理と臨床; 33(2): 157-163, 2015.
- 小松則夫. 貧血. スポーツにおける薬物治療; 124-128. 2015.
- 枝廣陽子, 小松則夫. 新しいWHO 分類に基づくMPNの診断. Hematology Agora 2015年春号; 2015.
- 枝廣陽子, 小松則夫. Masked PV. 血液内科; 70(5): 650-655, 2015.
- 高久智生, 小松則夫. STOP試験の現状. 慢性骨髄性白血病(CML)の基礎と臨床; 187-201, 2015.
2014年
- 小松則夫. 骨髄増殖性腫瘍(MPN). SRL宝函; 35(2): 12-20, 2014.
- 小松則夫. 急性骨髄性白血病. 今日の臨床サポート改訂版; 2014.
- 小松則夫. 赤血球増加. medicina; 51(3): 424-428, 2014.
- 小松則夫. 低酸素応答因子(HIF)分解酵素阻害薬. 腎疾患・透析最新の治療2014-2016; 389-391. 2014.
- 小松則夫. 真性赤血球増加症の心血管イベントと治療強度. 中外医学社 Annual Review血液2014; 67-75, 2014.
- 小松則夫. 骨髄増殖性腫瘍の病態と治療. 日本内科学会雑誌; 103(2): 440-449, 2014.
- 小松則夫. 本態性血小板血症 待たれる骨髄抑制療法無効・不耐容例への治療薬. 日経メディカル AUTUMN; 47, 2014.
- 小松則夫. BCR-ABL陰性骨髄増殖性腫瘍の治療戦略. 臨床血液; 55(1): 56-65, 2014.
- 小松則夫. 特発性血小板減少性紫斑病（免疫性血小板減少症）. 日本内科学会雑誌; 103(7): 1593-1608, 2014.
- 枝廣陽子, 小松則夫. 本態性血小板血症の治療：anagrelide vs. ハイドロキシウレア. 血液内科; 68(2): 244-249, 2014.
- 後藤明彦, 小松則夫. BCR-ABL陰性骨髄増殖性腫瘍の治療戦略. 臨床血液; 55: 56-65, 2014.
- 枝廣陽子, 小松則夫. 骨髄増殖性腫瘍の治療−JAK2阻害薬以外の新規治療薬−最終回. BIO Clinica; 29(3): 302-305, 2014.
- 枝廣陽子, 小松則夫. 骨髄増殖性腫瘍の治療−JAK2阻害薬以外の新規治療薬−第7回. BIO Clinica; 29(2): 198-201, 2014.
- 筒井深雪, 角南義孝, 小松則夫. 骨髄増殖性腫瘍の治療−JAK2阻害薬−第6回. BIO Clinica; 29(1): 97-101, 2014.
|
|
|
|
|
|
各研究分野紹介一覧